These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32030692)

  • 1. Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan.
    Sakamaki K; Morita Y; Iba K; Kamiura T; Yoshida S; Ogawa N; Suganami H; Tsuchiya S; Fukimbara S
    Ther Innov Regul Sci; 2020 Sep; 54(5):1097-1105. PubMed ID: 32030692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan.
    Sakamaki K; Yoshida S; Morita Y; Kamiura T; Iba K; Ogawa N; Suganami H; Tsuchiya S; Fukimbara S
    Ther Innov Regul Sci; 2020 May; 54(3):528-533. PubMed ID: 33301137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan.
    Sakamaki K; Yoshida S; Morita Y; Kamiura T; Iba K; Ogawa N; Suganami H; Tsuchiya S; Fukimbara S
    Ther Innov Regul Sci; 2019 Jun; ():2168479019855994. PubMed ID: 31213076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Practice on Multiplicity Adjustment and Sample Size Calculation in Multi-arm Clinical Trials: An Industry Survey in Japan.
    Sakamaki K; Kamiura T; Morita Y; Iba K; Yoshida S; Wakana A; Tsuchiya S; Fukimbara S; Suganami H
    Ther Innov Regul Sci; 2016 Nov; 50(6):846-852. PubMed ID: 30231736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size optimization for clinical trials using graphical approaches for multiplicity adjustment.
    Zhang F; Gou J
    Stat Med; 2023 Dec; 42(28):5229-5246. PubMed ID: 37727983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplicity adjustment for composite binary endpoints.
    Rauch G; Kieser M
    Methods Inf Med; 2012; 51(4):309-17. PubMed ID: 22525969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing unnecessary measurements in clinical trials with multiple primary endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2016; 26(4):631-43. PubMed ID: 26098617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some remaining challenges regarding multiple endpoints in clinical trials.
    Snapinn S
    Stat Med; 2017 Dec; 36(28):4441-4445. PubMed ID: 28664566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints.
    Sun H; Snyder E; Koch GG
    J Biopharm Stat; 2018; 28(1):189-211. PubMed ID: 28992425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints.
    Yang J; Li J; Wang S; Luo L; Liu P
    Hum Vaccin Immunother; 2019; 15(1):256-263. PubMed ID: 30273507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2011 Jul; 21(4):650-68. PubMed ID: 21516562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
    Roig MB; Melis GG; Posch M; Koenig F
    Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.
    Zichi C; Paratore C; Gargiulo P; Mariniello A; Reale ML; Audisio M; Bungaro M; Caglio A; Gamba T; Perrone F; Di Maio M
    Eur J Cancer; 2021 May; 149():49-60. PubMed ID: 33823362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical planning to address strongly correlated endpoints for inferential subgroups: An innovative approach for an illustrative clinical trial with complex multiplicity issues.
    Sun H; Binkowitz B; Koch GG
    J Biopharm Stat; 2017; 27(3):399-415. PubMed ID: 28267412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
    Zaslavsky BG
    Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables.
    Sozu T; Sugimoto T; Hamasaki T
    Biom J; 2012 Sep; 54(5):716-29. PubMed ID: 22829198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case study of an adaptive design for a clinical trial with 2 doses and 2 endpoints in a rare disease area.
    Quan H; Xu Y; Chen Y; Gao L; Chen X
    Pharm Stat; 2018 Nov; 17(6):797-810. PubMed ID: 30221446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.